clinical trials for semaglutide Long-term weight loss effects of in obesity without diabetes in the SELECT trial What the SELECT trial of

No membership fees

For indexed literature and PubMed research on Semaglutide signaling, consult PubMed Semaglutide Citations

[DOI] [PMC free article] [PubMed] [Google Scholar] 64.Farrell E., Hollmann E., le Roux C.W., Bustillo M., Nadglowski J., McGillicuddy D

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two primary indications: type 2 diabetes management and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

Strength 0.25 mg / 0.5 ml 0.5 mg / 0.5 ml 1 mg / 0.5 ml 1.7 mg / 0.75 ml 2.4 mg / 0.75 ml Pack Size 1s Dosage Form Pre-filled syringe Categories Biological Therapeutic Class GLP-1 receptor agonist